Novel non-pharmacological treatment for degenerative joint and disc disease

Abstract

BACKGROUND: The most common pathologies in the structure of musculoskeletal disorders are osteoarthritis and non-specific back pain caused by degenerative disc disease, proportion is 20% and 46%, respectively. According to the new WHO initiative "Rehabilitation-2030: call for action", the implementation of non-pharmacological methods in the treatment programs for patients with degenerative joint and disc disease is of great importance.

AIMS: A clinical study was conducted to evaluate the effectiveness of a new method of balneo-thalassotherapy — seaweed in the form of local applications and general baths in patients with osteoarthritis and back pain.

MATERIALS AND METHODS: A randomized controlled clinical trial included 40 patients (mean age 51.67±0.65 years). Patients were divided into 3 groups: 1group (n=15) — patients received local applications of seaweed on the joints and affected segments of the spine, and basic medical treatment; 2 group (n=15) — patients received procedures of seaweed general baths, and basic medical treatment; 3 group (control, n=10) — patients received only basic medical therapy. The treatment course was 20 days (15 procedures with a break for the weekend).

RESULTS: A significant positive effect of the method of seaweed therapy on the clinical symptoms of degenerative pathology of the joints and spine was demonstrated: decreasing of pain, improving of the level of motor activity and daily functioning, and an increase in the quality of life was noted. The effectiveness of the treatment was 73.3–80%.

CONCLUSION: The obtained results prove the effectiveness of using seaweed in patients with degenerative pathology of the joints and spine with pain syndrome. This treatment method can be included in rehabilitation programs for these patients as local applications or general bath procedure.

Keywords

osteoarthritis / back pain / musculoskeletal disorders / balneotherapy / thalassotherapy / seaweed

References

[1] Cieza A, Causey K, Kamenov K, et al. Global estimates of the need for rehabilitation based on the Global Burden of Disease study 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2021;396(10267):2006–2017.

[2] Cieza A., Causey K., Kamenov K., et al. Global estimates of the need for rehabilitation based on the Global Burden of Disease study 2019: a systematic analysis for the Global Burden of Disease Study 2019//Lancet. 2021. Vol. 396, N 10267. Р. 2006–2017. doi: 10.1016/S0140-6736(20)32340-0

[3] doi: 10.1016/S0140-6736(20)32340-0

[4] ВОЗ. Заболевания опорно-двигательного аппарата. [Электронный ресурс]. Режим доступа: https://www.who.int/ru/news-room/fact-sheets/detail/musculoskeletal-conditions

[5] WHO. Musculoskeletal conditions. [Electronic resource]. (In Russ). Available from: https://www.who.int/news-room/fact-sheets/detail/musculoskeletal-conditions

[6] Ревматические болезни: руководство для врачей / под ред. В.А. Насоновой, Н.В. Бунчука. Москва: Медицина, 1997. С. 385–396.

[7] Rheumatic diseases: a guide for doctors. Ed. by V.A. Nasonova, N.V. Bunchuk. Moscow: Medicine; 1997. Р. 385–396. (In Russ).

[8] Хитров Н.А. Остеоартроз и остеоартрит — патоморфоз названия и прогресс знаний о болезни//РМЖ. Ревматология. 2011. Т. 25. С. 1525–1529.

[9] Khitrov NA. Osteoarthritis and osteoarthritis-pathomorphosis of the name and the progress of knowledge about the disease. RMJ. Rheumatology. 2011;25:1525–1529. (In Russ).

[10] Ревматология: национальное руководство / под ред. Е.Л. Насонова, В.А. Насоновой. Москва: ГЭОТАР-Медиа, 2008. С. 573–588.

[11] Rheumatology: National guidelines. Ed. by E.L. Nasonov, V.A. Nasonova. Moscow: GEOTAR-Media; 2008. Р. 573–588. (In Russ).

[12] Hedbom E., Huselmann H.J. Molecular aspects of pathogenesis in osteoarthritis: the role of inflammation//Cell Mol Life Sci. 2002. Vol. 59, N 1. Р. 45–53. doi: 10.1007/s00018-002-8404-z

[13] Hedbom E, Huselmann HJ. Molecular aspects of pathogenesis in osteoarthritis: the role of inflammation. Cell Mol Life Sci. 2002;59(1):45–53. doi: 10.1007/s00018-002-8404-z

[14] Бородулина И.В., Рачин А.П. Патогенетические подходы к терапии обострения хронической боли в спине: описание клинического случая//Медицинский совет. 2019. № 12. С. 42–47. doi: 10.21518/2079-701X-2019-12-42-47

[15] Borodulina IV, Rachin AP. Pathogenetic approaches to the treatment of exacerbation of chronic back pain: description of a clinical case. Medical Advice. 2019;12:42–47.

[16] ВОЗ. Реабилитация 2030: призыв к действиям. [Электронный ресурс]. Режим доступа: https://www.who.int/rehabilitation/CallForActionRU.pdf

[17] doi: 10.21518/2079-701X-2019-12-42-47

[18] Stucki G. Advancing the rehabilitation sciences//Front Rehabilit Sci. 2021. doi: 10.3389/fresc.2020.617749

[19] WHO. Rehabilitation 2030: A call for action. [Electronic resource]. (In Russ). Available from: https://www.who.int/publications/m/item/rehabilitation-2030-a-call-for-action

[20] Бородулина И.В., Бадалов Н.Г., Мухина А.А., Гуща А.О. Оценка эффективности комплексного лечения с применением ритмической транскраниальной магнитной стимуляции и общих гидрогальванических ванн у пациентов с пояснично-крестцовой радикулопатией//Вестник восстановительной медицины. 2019. № 1. С. 33–41.

[21] Stucki G. Advancing the rehabilitation sciences. Front Rehabilit Sci. 2021. doi: 10.3389/fresc.2020.617749

[22] Park S.K., Park S.J., Park S.M., et al. Inhibition of acute phase inflammation by Laminaria japonica through regulation of iNOS-NF-κB Pathway//Evid Based Complement Alternat Med. 2013. Vol. 2013. Р. 439498.doi: 10.1155/2013/439498

[23] Borodulina IV, Badalov NG, Mukhina AA, Gushcha AO. Evaluation of the effectiveness of complex treatment using rhythmic transcranial magnetic stimulation and general hydrogalvanic baths in patients with lumbosacral radiculopathy. Bulletin of Restorative Medicine. 2019;(1):33–41. (In Russ).

[24] Kyung J., Kim D., Park D., et al. Synergistic anti-inflammatory effects of Laminaria japonica fucoidan and Cistanchetubulosa extract//Lab Anim Res. 2012. Vol. 28, N 2. Р. 91–97. doi: 10.5625/lar.2012.28.2.91

[25] Park SK, Park SJ, Park SM, et al. Inhibition of acute phase inflammation by Laminaria japonica through regulation of iNOS-NF-κB Pathway. Evid Based Complement Alternat Med. 2013;2013:439498. doi: 10.1155/2013/439498

[26] Vázquez A.I., Sánchez C.M., Delgado N.G., et al. Anti-inflammatory and analgesic activities of red seaweed Dichotomaria obtusata//Brazilian Journal of Pharmaceutical Sciences. 2011. Vol. 47, N 1. Р. 111–118. doi: 10.1590/S1984-82502011000100014

[27] Kyung J, Kim D, Park D, et al. Synergistic anti-inflammatory effects of Laminaria japonica fucoidan and Cistanchetubulosa extract. Lab Anim Res. 2012;28(2):91–97. doi: 10.5625/lar.2012.28.2.91

[28] Myers S.P., O’Connor J., Fitton H. A combined phase I and II open label study on the effects of a seaweed extract nutrient complex on osteoarthritis//Biologics. 2010. Vol. 4. Р. 33–44.doi: 10.2147/btt.s8354

[29] Vázquez AI, Sánchez CM, Delgado NG, et al. Anti-inflammatory and analgesic activities of red seaweed Dichotomaria obtusata. Brazilian Journal of Pharmaceutical Sciences. 2011;47(1):111–118.

[30] Бунчук Н.В. Диагностические критерии остеоартроза коленных суставов//Consilium medicum. 2002. № 8. Р. 396–399.

[31] doi: 10.1590/S1984-82502011000100014

[32] Bellamy N., Buchanan W.W., Goldsmith C.H., et al. Validation study of WOMAC. A health status instrument for measuring clinically impotant patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee//J Rheumatol. 1988. Vol. 15, N 12. Р. 1833–1840.

[33] Myers SP, O’Connor J, Fitton H. A combined phase I and II open label study on the effects of a seaweed extract nutrient complex on osteoarthritis. Biologics. 2010;4:33–44.

[34] Kersten P., White P.J., Tennant A. The visual analogue WOMAC 3.0 scale-internal validity and responsiveness of the VAS version//BMC Musculoskelet Disord. 2010. Vol. 11. P. 80. doi: 10.1186/1471-2474-11-8.

RIGHTS & PERMISSIONS

Eco-Vector